EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma

Zachary L Taylor iD, Erin F Barreto, Kristin C Cole, Andrew D Rule, Kianoush B Kashani, Nelson Leung, Carrie A Thompson, Thomas E Witzig, Laura B Ramsey, Jason N Barreto

Clinical Pharmacokinetics · 2026

DOI: 10.1007/s40262-026-01618-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Zachary L Taylor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC-6018, Cincinnati, OH, 452…. Hauptthemen laut MEDLINE: Methotrexate, Cystatin C, Glomerular Filtration Rate, Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High-dose methotrexate (HDMTX) is a key treatment for lymphoma with central nervous system involvement. Whether incorporating cystatin C into glomerular filtration rate estimation improves methotrexate (MTX) clearance prediction remains unclear. OBJECTIVES: We aimed to evaluate whether cystatin C-inclusive glomerular filtration rate equations improve MTX clearance prediction and to explore the relationship between MTX exposure and acute kidney injury (AKI) in adult patients with lymphoma receiving HDMTX. METHODS: This was a prospective single-center study performed on 80 adult patients with lymphoma receiving HDMTX (1.5-8 g/m2) over a 4-h infusion. A population pharmacokinetic model was constructed using data from 80 administrations of HDMTX and 427 serum MTX concentrations. The population pharmacokinetic model estimated MTX concentrations were included in a logistic regression to assess the relationship between MTX exposure and AKI. RESULTS: A two-compartment model best described the pharmacokinetic data, with baseline albumin and CKD-EPI creatinine-cystatin C (eGFRCr-CysC) as significant covariates on clearance. Seventeen patients (21%) developed any-stage AKI. Among those receiving ≤ 3.5 g/m2, model-estimated 4-h MTX concentrations were associated with AKI (odds ratio: 1.02 per µmol/L; p = 0.0038), with an optimal threshold of 160 µmol/L (area under the concentration-time curve: 0.818). Patients above this threshold were 22 times more likely to experience AKI (p = 0.0005). This association was not observed in patients treated with 8 g/m2. Despite a lower dose and exposure, patients receiving ≤ 3.5 g/m2 demonstrated a stronger concentration-toxicity relationship. CONCLUSIONS: Our results support the use of cystatin C-inclusive glomerular filtration rate estimates in MTX pharmacokinetic modeling and suggest early MTX concentration sampling may identify AKI risk, enabling proactive, AKI-mitigating clinical interventions during HDMTX therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateCystatin CGlomerular Filtration RateLymphomaAntimetabolites, AntineoplasticModels, BiologicalHumansMaleFemaleMiddle AgedProspective StudiesAdultAgedAcute Kidney InjuryCreatinine

Substanzen

MethotrexateCystatin CAntimetabolites, AntineoplasticCreatinine

Autor:innen und Institutionen

  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC-6018, Cincinnati, OH, 45229-3039, USA. zachary.taylor@cchmc.org.
  • Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. zachary.taylor@cchmc.org.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. zachary.taylor@cchmc.org.
  • Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
  • Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Zachary L Taylor

Förderung

  • NCATS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Taylor, Z. L., Barreto, E. F., Cole, K. C., Rule, A. D., Kashani, K. B., Leung, N., Thompson, C. A., Witzig, T. E., Ramsey, L. B., & Barreto, J. N. (2026). Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01618-4

Vancouver

Taylor ZL, Barreto EF, Cole KC, Rule AD, Kashani KB, Leung N, et al. Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01618-4

BibTeX
@article{Taylor2026,
  author = {Taylor, Zachary L and Barreto, Erin F and Cole, Kristin C and Rule, Andrew D and Kashani, Kianoush B and Leung, Nelson and Thompson, Carrie A and Witzig, Thomas E and Ramsey, Laura B and Barreto, Jason N},
  title = {Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-026-01618-4}
}
Kostenlos starten →